PF-04217903 HYDROCHLORIDE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H16N8O.ClH
Molecular Weight	408.844
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.OCCN1C=C(C=N1)C2=NC3=C(N=NN3CC4=CC=C5N=CC=CC5=C4)N=C2

InChI

InChIKey=HGQFZZOIHJTGJW-UHFFFAOYSA-N

InChI=1S/C19H16N8O.ClH/c28-7-6-26-12-15(9-22-26)17-10-21-18-19(23-17)27(25-24-18)11-13-3-4-16-14(8-13)2-1-5-20-16;/h1-5,8-10,12,28H,6-7,11H2;1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C19H16N8O
Molecular Weight	372.3833
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19459657 | https://www.ncbi.nlm.nih.gov/pubmed/26013381
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800027901

PF-04217903 is a triazolopyrazine inhibitor of c-MET that displays anticancer chemotherapeutic and anti-metastatic activities. PF-04217903 inhibits cell proliferation, invasion, and migration as well as tumor growth in various cancer models. In animal models of pancreatic neuroendocrine tumors, this compound prevents lymph node metastasis. PF-04217903 had been in phase I clinical trials by Pfizer for the treatment of solid tumors. In 2011, the company discontinued the development of the compound.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Hepatocyte growth factor receptor 56 Target ID: CHEMBL3717 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19459657	Inhibitor 8504		4.8 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Advanced cancer 9 Sources: https://clinicaltrials.gov/ct2/show/NCT00706355	Primary		Phase I 438	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
397 ng/mL CLINICAL TRIAL https://www.clinicaltrials.gov/study/NCT00706355	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:		PF-04217903 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.24 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21098644	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:		PF-04217903 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1595 ng × h/mL CLINICAL TRIAL https://www.clinicaltrials.gov/study/NCT00706355	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:		PF-04217903 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.81 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21098644	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:		PF-04217903 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
6.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21098644	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:		PF-04217903 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
16% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24900568/	unknown		PF-04217903 plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
16.4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21098644	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:		PF-04217903 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
30 mg single, oral Studied dose Dose: 30 mg Route: oral Route: single Dose: 30 mg Sources: https://pubmed.ncbi.nlm.nih.gov/21098644	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21098644	Sources: https://pubmed.ncbi.nlm.nih.gov/21098644

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY116324	https://www.001chemical.com/chem/search?q=DY116324
001 Chemical	DY20948	https://www.001chemical.com/chem/search?q=DY20948
1PlusChem LLC	1P01CPML	https://www.1pchem.com/search?query=1P01CPML
1PlusChem LLC	1P01DP3N	https://www.1pchem.com/search?query=1P01DP3N
Aceschem	ACS012039	https://www.aceschem.com/catalog/search.do?q=ACS012039
AK Scientific	3965AH	https://aksci.com/item_detail.php?cat=3965AH
AK Scientific	SYN1060	https://aksci.com/item_detail.php?cat=SYN1060
AK Scientific	X7368	https://aksci.com/item_detail.php?cat=X7368
Alfa Chemistry	ACM1159490853	http://www.alfa-chemistry.com/search.aspx?q=ACM1159490853
Ambeed	A139192	http://www.ambeed.com/search/Search.html?keyword=A139192
Angene	AGN-PC-0WD178	http://www.angenechemical.com/productshow/AGN-PC-0WD178.html
Angene	AGN-PC-0WH9J8	http://www.angenechemical.com/productshow/AGN-PC-0WH9J8.html
AOBIOUS INC	AOB87137	http://aobious.com/aobious/search?search_query=AOB87137
ApexBio Technology	A5096	https://www.apexbt.com/catalogsearch/result/?q=A5096
AstaTech	43123	http://astatechinc.com/CPSResult.php?CRNO=43123
AstaTech	C77303	http://astatechinc.com/CPSResult.php?CRNO=C77303
Axon MedChem	1583	https://www.axonmedchem.com/product/1583
BLD Pharm	BD316981	http://www.bldpharm.com/search/Search.html?keyword=BD316981
BLD Pharm	BD631066	http://www.bldpharm.com/search/Search.html?keyword=BD631066
BOC Sciences	956905-27-4	http://www.bocsci.com/description.asp?cas=956905-27-4
BOC Sciences	956906-93-7	http://www.bocsci.com/description.asp?cas=956906-93-7
Capot Chemical	19150	https://www.capotchem.com/search.do?q=19150
Capot Chemical	22334	https://www.capotchem.com/search.do?q=22334
Capot Chemical	22335	https://www.capotchem.com/search.do?q=22335
Cayman Chemical	17931	http://www.caymanchem.com/app/template/Product.vm/catalog/17931
Chem Scene	CS-0147	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0147
ChemShuttle	104836	https://www.chemshuttle.com/catalogsearch/result/?q=104836
ChemShuttle	140538	https://www.chemshuttle.com/catalogsearch/result/?q=140538
Combi-Blocks	QW-2364	http://www.combi-blocks.com/cgi-bin/find.cgi?QW-2364
eMolecules	222564578	https://orderbb.emolecules.com/search/#?query=222564578
eMolecules	31507608	https://orderbb.emolecules.com/search/#?query=31507608
eMolecules	36367164	https://orderbb.emolecules.com/search/#?query=36367164
eMolecules	44847011	https://orderbb.emolecules.com/search/#?query=44847011
eNovation Chemicals	D372333	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D372333&searchbtn.x=0&searchbtn.y=0
eNovation Chemicals	D752725	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D752725&searchbtn.x=0&searchbtn.y=0
Excenen	EX-A449	http://www.excenen.com/searchresultlist.php?id=EX-A449
Excenen	EX-A478	http://www.excenen.com/searchresultlist.php?id=EX-A478
Exclusive Chemistry	2351	http://www.exchemistry.com/chem-catalog/product-2351.html
Hairui	HR108914	http://www.hairuichem.com/en/product/search.do?q=HR108914
Hairui	HR22334	http://www.hairuichem.com/en/product/search.do?q=HR22334
KeyOrganics	AS-16216	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-16216
KeyOrganics	AS-74650	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-74650
Matrix Scientific	145223	http://www.matrixscientific.com/145223.html
mcule	MCULE-1128057679	https://mcule.com/MCULE-1128057679/
mcule	MCULE-4382552575	https://mcule.com/MCULE-4382552575/
mcule	MCULE-6204241611	https://mcule.com/MCULE-6204241611/
MedChem Express	HY-12017	https://www.medchemexpress.com/search.html?q=HY-12017A&ft=&fa=&fp=
MedChem Express	HY-12017A	https://www.medchemexpress.com/search.html?q=HY-12017A&ft=&fa=&fp=
Molcore	MC116324	http://www.molcore.com/CatMC116324.html
Molcore	MC20948	http://www.molcore.com/CatMC20948.html
Molnova	M16830	https://www.molnova.com/en/serch-list.html?keywords=M16830
Molnova	M16831	https://www.molnova.com/en/serch-list.html?keywords=M16831
MolPort	MolPort-016-633-176	https://www.molport.com/shop/molecule-link/MolPort-016-633-176
MolPort	MolPort-023-277-115	https://www.molport.com/shop/molecule-link/MolPort-023-277-115
MuseChem	I005670	https://www.musechem.com/product/I005670.html
MuseChem	I008498	https://www.musechem.com/product/I008498.html
MuseChem	I012034	https://www.musechem.com/product/I012034.html
ShangHai Biochempartner	BCP000145	http://www.biochempartner.com/search_BCP000145
ShangHai Biochempartner	BCP000275	http://www.biochempartner.com/search_BCP000275
ShangHai Biochempartner	BCP01847	http://www.biochempartner.com/search_BCP01847
ShangHai Biochempartner	BCP02230	http://www.biochempartner.com/search_BCP02230
TargetMol	T2676	https://www.targetmol.com/search?keyword=T2676
Tocris	4239	https://www.tocris.com/search.php?Type=QuickSearch&Value=4239
Toronto Research Chemicals	C351130	https://www.trc-canada.com/product-detail/?CatNum=C351130
Toronto Research Chemicals	P293990	https://www.trc-canada.com/product-detail/?CatNum=P293990

PubMed

Title	Date	PubMed
In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase.	2010-08	20444863

Patents

Sample Use Guides

In Vivo Use Guide

Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days

Route of Administration: Oral

In Vitro Use Guide

Treatment with 100 nM of PF-04217903 for 4 hours resulted in decreased p-MET, pERK, p-AKT and p-PLCγ1 in mouse melanocytes expressing TRIM4-MET or ZKSCAN1-MET

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:05:26 GMT 2025` Edited by `admin` on `Mon Mar 31 22:05:26 GMT 2025`
Record UNII	EA0E6NGB9V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

1H-PYRAZOLE-1-ETHANOL, 4-(1-(6-QUINOLINYLMETHYL)-1H-1,2,3-TRIAZOLO(4,5-B)PYRAZIN-6-YL)-, HYDROCHLORIDE (1:1)

Preferred Name

English

PF-04217903 HYDROCHLORIDE

Common Name

English

Code System Code Type Description

FDA UNII

EA0E6NGB9V

Created by admin on Mon Mar 31 22:05:26 GMT 2025 , Edited by admin on Mon Mar 31 22:05:26 GMT 2025

PRIMARY

PUBCHEM

66933368

Created by admin on Mon Mar 31 22:05:26 GMT 2025 , Edited by admin on Mon Mar 31 22:05:26 GMT 2025

PRIMARY

EPA CompTox

DTXSID70736061

Created by admin on Mon Mar 31 22:05:26 GMT 2025 , Edited by admin on Mon Mar 31 22:05:26 GMT 2025

PRIMARY

CAS

1159490-81-9

Created by admin on Mon Mar 31 22:05:26 GMT 2025 , Edited by admin on Mon Mar 31 22:05:26 GMT 2025

PRIMARY

Related Record Type Details


					CYJ9ATV1IJ

PF-04217903

PARENT -> SALT/SOLVATE

Amount:

Related Record Type Details


					CYJ9ATV1IJ

PF-04217903

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19459657 | https://www.ncbi.nlm.nih.gov/pubmed/26013381Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800027901

Originator

Approval Year

Targets

Conditions

Approved Use

Cmax

AUC

T1/2

Funbound

Doses

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19459657 | https://www.ncbi.nlm.nih.gov/pubmed/26013381
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800027901

C_max

T_1/2

F_unbound